Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pascal Soriot

AstraZeneca Moves Some Production To US Amid Tariff Threat

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector.

International Business Times

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot

The Guardian - UK

AstraZeneca plots US expansion despite Trump tariff threat

The drug maker said it is ‘firmly committed to investing and growing in the US’ amid potential import tariffs on the pharmaceutical industry.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Drug firm bosses call for price increases in Europe amid tariff uncertainty

The boss of AstraZeneca said Europe should increase spending on health treatment in line with recent commitments on defence.

Evening Standard

China, America and pay inject drama into AstraZeneca’s AGM

The boss’s bonus is an annual debating point at Britain’s biggest company. But that’s not the only issue this year

The Guardian - UK

GSK could double CEO Emma Walmsley's pay to $27 million

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

Fortune

AstraZeneca boss takes home £15m pay packet after profits rise

The Cambridge-based pharmaceutical company behind a variety of medicines paid its chief executive Pascal Soriot £14.7 million in 2024.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

The Guardian - UK

Inside AstraZeneca’s abandoned UK vaccine plant deal as Labour and Tories face questions over £450m collapse

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate Devlin question why it fell through

The Independent UK

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

The Independent UK

AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government

It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector

The Guardian - UK

From the Beatles to biologics – how Liverpool became a life science hotspot

The city has a long history with tropical medicine and is now home to one of the largest biotech clusters in Europe

The Guardian - UK

Billonaire calls for CEOs to be paid like footballers, despite earning double them

Lord Michael Spencer says U.K. CEOs need to earn more to retain the best talent.

Fortune

AstraZeneca’s numbers are good but trouble in China could drag it down

Profits beat forecasts but a 17% fall in share price since executives were detained by Beijing may be hard to shake

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca says it takes China investigation ‘very seriously’

UK’s biggest pharmaceutical company ‘committed to China’ as it raises 2024 profit forecast and announces $3.5bn US investment

The Guardian - UK

UK grocery inflation picks up to 2.3%; unemployment rises while regular wage growth slows – as it happened

Consumers started their Christmas shopping early, Kantar says; UK jobless rate rises to 4.3% while wage growth excluding bonuses is at a two-year low

Evening Standard

FTSE 100 Live 12 November: Vodafone and AstraZeneca results fail to revive shares, Metro Bank fined £16m

Cracks are appearing in the labour market after the unemployment rate today rose to 4.3%.

Barchart

As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

The Guardian view on record payouts for CEOs: the way they live now

Editorial: The latest High Pay Centre report confirms the persistent and damaging culture of entitlement at the top of business

Fortune

Typical FTSE 100 CEO pay hits record high of £4.2 million—but U.S. peers still earn 3 times as much

AstraZeneca’s Pascal Soriot and Rolls Royce’s Tufan Erginbilgic were among the highest-paid FTSE 100 CEOs, but what they make still trails behind the average pay of S&P 500 CEOs.

The Guardian - UK

FTSE 100 chief executive pay reaches highest level on record

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

Barchart

1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

The Guardian - UK

Will AstraZeneca be the UK’s first £200bn company?

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn

The Guardian - UK

AstraZeneca aims to nearly double revenues to $80bn by 2030

UK’s biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade

Evening Standard

'New era of growth': AstraZeneca sets out bold plans for $80bn revenues by 2030

The growth will be fuelled by 20 new drugs that are set to launch this decade

1 2 3

People

Margherita Della Valle

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.